M. Bischof

Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial

P. Ferenci, M. Gschwantler, S. Metz-Gercek, 2011, BMC Research Notes.

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

C. Datz, R. Stauber, P. Ferenci, 2008, Gastroenterology.

and 4 Patients With Rapid Virological Response

C. Datz, R. Stauber, P. Ferenci, 2008 .

Increased C282Y Heterozygosity in Gestational Diabetes

E. Cauza, U. Hanusch-Enserer, K. Kostner, 2005, Fetal Diagnosis and Therapy.

Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection.

C. Datz, R. Stauber, P. Ferenci, 2012, Gastroenterology.

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.

C. Datz, R. Stauber, P. Ferenci, 2010, Gastroenterology.

8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders’

C. Datz, R. Stauber, P. Ferenci, 2006 .

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa‐2a in hepatitis C virus genotypes 2 and 3

R. Stauber, P. Ferenci, M. Gschwantler, 2008, Hepatology.

Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy

R. Stauber, P. Ferenci, W. Vogel, 2017, Wiener klinische Wochenschrift.

Atomically-precise three-dimensional top down fabrication

N. Sarkar, J. N. Randall, E. Fuchs, 2013, 2013 Transducers & Eurosensors XXVII: The 17th International Conference on Solid-State Sensors, Actuators and Microsystems (TRANSDUCERS & EUROSENSORS XXVII).

Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection.

C. Datz, R. Stauber, P. Ferenci, 2012, Gastroenterology.